Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735559) titled 'SAFE-iPS - France's First Hospital-based Platform for the Production of Induced Pluripotent Stem Cells for the Regenerative Medicine of the Future' on July 21.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: University Hospital, Montpellier
Condition:
Regenerative Medicine
Induced Pluripotent Stem Cells (iPSC) Production
Intervention:
Procedure: Blood Collection for iPSC Generation
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: November 2026
Target Sa...